New combo therapy aims to tackle tough cancers

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital, followed by possible pembrolizumab alone. The study tracks tumor response, safety, and how long the benefit lasts.